Skip to main content
SpringerLink
Log in

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Approximately 70-80% of patients with metastatic testicular cancer will become disease free with cisplatin-based chemotherapy and most of these patients will be longterm survivors. Despite these impressive results, the two limitations of cisplatin are its severe and potentially long-term side-effects, and the emergence of drug resistance which prevents a small proportion of these patients from achieving long-term remission. Oxaliplatin has an improved toxicity profile compared to cisplatin and contains the diaminocyclohexane (DACH) substituent known to be correlated with a lack of cross resistance with cisplatin. A phase II study has shown interesting activity when used in combination with cisplatin in cisplatin-refractory testicular cancer patients. Here we report the results of the first in vitro study investigating whether oxaliplatin as a single agent exhibits cross-resistance to cisplatin in a panel of non-seminomatous germ cell tumor (NSGCT) cell lines using short and long-term drug exposures in a five-day sulfhodamine B in vitro cytotoxicity assay. Oxaliplatin cytotoxicity was significantly superior to cisplatin in cell lines with both acquired (H12DDP) and intrinsic (1777NR Cl-A) intermediate level resistance to cisplatin. Following 24h or 96h drug exposure the fold resistance in H12DDP and 1777NR Cl-A was 1.7-2.2 with oxaliplatin compared to 3.9-6.1 with cisplatin. The cytotoxic activity of oxaliplatin was not significantly different from that of cisplatin in cisplatin-senstive cell lines or in cell lines with a high level (10-20 fold) of cisplatin resistance. The results of this study suggest that further pre-clinical studies in NSGCT are of interest, particularly in combination with cisplatin, ifosfamide and etoposide. Furthermore, the in vitro results support the use of an oxaliplatin administration schedules giving prolonged drug exposure, such as the flat or circadian rhythm-modulated schedule already under investigation for oxaliplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bokemeyer C, Berger C, Kynast B, Schmoll HJ, Poliwoda H: Ototoxicity following therapy for testicular cancer. Eur J Cancer 29A(suppl 6):1357, 1993

    Google Scholar 

  2. Bokemeyer C, Frank B, van Rhee J, Berger C, Schmoll HJ: Peripheral neuropathy following cancer chemotherapy. Long term results in patients with curable neoplasms. Tumordiagn. u. Ther 14:232, 1993

    Google Scholar 

  3. Cornelison TL, and Reed E: Nephrotoxicity and hydration management for cisplatin, carboplatin and ormaplatin. Gynecologic Oncology 50:147, 1993

    Google Scholar 

  4. Bokemeyer C, Droz JP, Hanauske A, Schmoll HJ: Treatment of relapsed germ cell tumors with vinorelbine: A trial of the phase I/II study group of the association for medical oncology of the German cancer society. Onkologie 16:29–31, 1993

    Google Scholar 

  5. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wimpner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: High-dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II study. Ann Oncol 1(5):375–376, 1990

    Google Scholar 

  6. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 120:754–757, 1994

    Google Scholar 

  7. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: Clinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and-resistant human testicular, ovarian, gastric carcinoma cell lines. Cancer Chemother Pharmacol 33:43–47, 1993

    Google Scholar 

  8. Harstrick A, Casper J, Schmoll HJ: Comparative antitumor activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular xenografts. Int J Androl 10:139–145, 1987

    Google Scholar 

  9. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ Scher HI, Geller NL, Fair WR, Herr H, Sogani P: Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11:598, 1993

    Google Scholar 

  10. Bokemeyer C, Schmoll HJ, Harms P, Kohrmann U, Haupt A, Räth U: Randomised comparison of cisplatin (P)versus carboplatin (C)combined with Etoposide (E) and Bleomycin (B) for minimal and moderate disease NSGCT. Ann Oncol 5(Suppl 8)68, 1994

    Google Scholar 

  11. Horwich A, Sleijfer D, Fossa S: A kial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular non-seminoma. Proc of ASCO 13:S709, 1993

    Google Scholar 

  12. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsern J, Zimmerman R, Bokemeyer C, Schmoll HJ, Huhn D: High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell tumors — a phase I/II study. J Clin Oncol 12:1223–1231, 1994

    Google Scholar 

  13. Kidani Y, Noji M, Tashiro T: Antitumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers. Gann 71:637, 1980

    Google Scholar 

  14. Brienza S, Bignoud J, Itzhaki M, Krikorian A: Oxaliplatin (LOHP). Global safety in 682 patients (PTS) Eur J Cancer 31A(Suppl 5):S194, 1995

    Google Scholar 

  15. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trail of a 5-day continuous venous infusion of oxaliplatin at circadian rhythmmodulated rate compared with constant rate. JNCI 82:1046, 1990

    Google Scholar 

  16. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H, Reinberg A: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69(4):893, 1991

    Google Scholar 

  17. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset JL: Oxaliplatin acitivty against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A(9):1280, 1993

    Google Scholar 

  18. Llory JF, Soulie P, Cvitkovic E, Misset JL: Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin. J Natl Cancer Inst 86:8, 1994

    Google Scholar 

  19. Fereres M, Llory JF, Soulie P, Garrino C, Gastiaburu J, Brienza S. Bensmaine MA, Misset JL, Cvitkovic E: Preliminary results of a oxaliplatin (LOHP)-CDDP association based salvage program in platinum (PT) pretreated germ cell tumors (GCT). 8th NCI-EORTC Conference, Amsterdam, 1994

  20. Bronson DL, Andrews PW, Vassella RL and Fraley EE: In vitro differentiation of human embryonal carcinoma cells. In Teratocarcinoma Stem Cells; CSH conference on cell 10:597–605, 1983

    Google Scholar 

  21. Vogelzang NJ, Bronson DL, Savino D, Vassella R, Fraley EF: A human embryonal-yolk sac carcinoma model system in athymic nude mice. Cancer 55:2584–2593, 1985

    Google Scholar 

  22. Casper J, Schmoll H-J, Schnaidt U, Fonatsch C: Cell lines of human germinal cancer. Int J Androl 10:105–113, 1987

    Google Scholar 

  23. Skehan P, Storeng R, Scudiero D, Monks A, McMahan J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82:1107–1112, 1990

    Google Scholar 

  24. Hill BT, Shellard SA, Fichtinger-Schepman A, Schmoll HJ, Harstrick A: Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anti-Cancer Drugs 5:321–328, 1994

    Google Scholar 

  25. Andrews PW, Banting G, Damjanov I, Arnaud D, Avner P: Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma 3:347–361, 1984

    Google Scholar 

  26. Pera MF, Blasco-Lafita MJ, Cooper S, Mason M, Mills J, Monoghan P: Analysis of cell-differentiation lineage in human teratomas using new monoclonal antibodies to cytostructural antigens of embryonal carcinoma cells. Differentiation 39:139–149, 1988

    Google Scholar 

  27. Einhorn LH: Testicular cancer: A model for a curable neoplasm. Cancer Res 41:3275–3280, 1981

    Google Scholar 

  28. Pendyala L, and Creaven PJ: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotrasformation of oxaliplatin. Cancer Research 53:5970, 1993

    Google Scholar 

  29. Alvarez M, Ortuzar W, Rixe O, Parker R, Reed E, Fojo T: Cross-Resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analoggues. Proceedings of the AACR 35:No. 2616 p439, 1994

    Google Scholar 

  30. Ortuzar W, Paull K, Rixe O, and Fojo T: Comparison of the activity of cisplatin (CP) and oxaliplatin (OXALI) alone or in combination in parental and drug resistance sublines. Proceedings of the AACR 35:No. 1974 p332, 1994

    Google Scholar 

  31. Fukada M, Ohe Y, Kanzawa F, Oka M, Kohei H and Saijo N: Evalulation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin Anticancer Res 15:393, 1995

    Google Scholar 

  32. Pera MF, Friedlos F, Mills J, Roberts JJ: Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cisdiamminedichloroplatinum (II) on DNA. Cancer Res 47:6810–6813, 1987

    Google Scholar 

  33. Bedford P, Fichtinger-Schepman AMJ, Shellard S, Walker MC, Masters JRW, Hill BT: Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48:3019–3024, 1988

    Google Scholar 

  34. Kelland LR, Mistry P, Abel G, Friedlos F, Loh SY, Roberts JJ, Harrap KR: Establishment and characterisation of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res 52:1710, 1992

    Google Scholar 

  35. Eastman A: The formation, isolation and characterisation of DNA adducts produced by anticancer platinum complexes. Pharac Ther 34:155, 1987

    Google Scholar 

  36. Jennerwein MM, Eastman A, Khokhar AR: Characterisation of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum (II) complexes. Chem Biol Interactions 70:39, 1989

    Google Scholar 

  37. Schaller W, Resiner H, Holler E: Kinetic investigation of the DNA platination reaction: evidence for a transient adduct between deoxyribonucleic acid and cisplatinum (II). Biochemistry 26:943, 1987

    Google Scholar 

  38. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Pierre A, Louvet C, Cvitkovic E, Gespach C: Antitumor activity of oxaliplatin in association with 5FU or thymidylate synthase inhibitors. In press

  39. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB: Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270:1842, 1995

    Google Scholar 

  40. Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ: Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377:649, 1995

    Google Scholar 

  41. Pil P, and Lippard SJ: Specific binding of chromosomal protein HMG 1 to DNA damaged by the anticancer drug cisplatin. Science 256:234, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Hannover Medical University, Konstanty-Gutschow Strasse 8, 30623

    T.A. Dunn & V. Grünwald

  2. Department of Hematology and Oncology, Martin-Luther University of Halle-Wittenberg, Ernst-Grube Strasse 40, 06120, Halle/Saale, Germany

    H.J. Schmoll

  3. Department of Hematology and Oncology, Eberhard-Karls-Universität, Otfried-Müller Strasse 10, 72076

    V. Bokemeyer

  4. Department of Hematology and Oncology, University of Rostock, 18055, Rostock

    J. Casper

Authors
  1. T.A. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Grünwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dunn, T., Schmoll, H., Grünwald, V. et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 15, 109–114 (1997). https://doi.org/10.1023/A:1005800520747

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005800520747

Search

Navigation